Home > News > Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy
October 19th, 2004
Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy
Abstract:
Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation, announced today that Insert is planning with City of Hope Comprehensive Cancer Center a broad-based Phase I clinical trial for Insert's lead drug candidate.
Source:
businesswire
Related Links |
Arrowhead Research Corporation
Related News Press |
Nanomedicine
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Announcements
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Finding quantum order in chaos May 17th, 2024
Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||